Evidence map›Paper›PMID 27695088›Full record

ArticlePloS one2016

Vaccine Strain-Specificity of Protective HLA-Restricted Class 1 P. falciparum Epitopes.

Martha Sedegah, Bjoern Peters, Michael R Hollingdale, Harini D Ganeshan, Jun Huang, Fouzia Farooq, Maria N Belmonte, Arnel D Belmonte, Keith J Limbach, Carter Diggs and 3 more

Erratum issued 2 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00392015 phase1 / phase2completednot on this map

A Two Part Clinical Trial Assessing the Safety, Tolerability, Immunogenicity and Protective Efficacy of NMRC-M3V-Ad-PfCA, a Multivalent, Adenovirus-Vectored Plasmodium Falciparum Malaria Vaccine, in Healthy, Malaria-Naïve Adults

TypeinterventionalSponsorU.S. Army Medical Research and Development CommandRan2006 to 2017Enrolled59ConditionsPlasmodium FalciparumArmsNMRC-M3V-Ad-PfCA, NMRC-MV-Ad-PfC, NMRC-M3V-Ad-PfCA
NCT00870987 phase1 / phase2completednot on this map

Clinical Trial on Safety, Immunogenicity, and Efficacy of a Prime Boost Regimen of DNA- and Adenovirus-vectored Malaria Vaccines Encoding Plasmodium Falciparum Circumsporozoite Protein and Apical Membrane Antigen 1 in Healthy Malaria-Naïve Adults in the US

TypeinterventionalSponsorU.S. Army Medical Research and Development CommandRan2009 to 2015Enrolled82ConditionsMalariaArmsDNA vaccine prime, adenovirus type 5 vaccine boost
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Comprehensive Review of HumanFrontiers in immunology · 2019
    Review
  7. Review
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Martha SedegahMalaria Department, Naval Medical Research Center, Silver Spring, MD, 20910, United States of America.
Bjoern PetersLa Jolla Institute for Allergy and Immunology, La Jolla, CA, 92037, United States of America.
Michael R HollingdaleMalaria Department, Naval Medical Research Center, Silver Spring, MD, 20910, United States of America.ORCID http://orcid.org/0000-0002-2343-3824
Harini D GaneshanMalaria Department, Naval Medical Research Center, Silver Spring, MD, 20910, United States of America.
Jun HuangMalaria Department, Naval Medical Research Center, Silver Spring, MD, 20910, United States of America.
Fouzia FarooqMalaria Department, Naval Medical Research Center, Silver Spring, MD, 20910, United States of America.
Maria N BelmonteMalaria Department, Naval Medical Research Center, Silver Spring, MD, 20910, United States of America.
Arnel D BelmonteMalaria Department, Naval Medical Research Center, Silver Spring, MD, 20910, United States of America.
Keith J LimbachMalaria Department, Naval Medical Research Center, Silver Spring, MD, 20910, United States of America.
Carter DiggsUSAID, Washington, DC, 20523, United States of America.
Lorraine SoissonUSAID, Washington, DC, 20523, United States of America.
Ilin ChuangMalaria Department, Naval Medical Research Center, Silver Spring, MD, 20910, United States of America.
Eileen D VillasanteMalaria Department, Naval Medical Research Center, Silver Spring, MD, 20910, United States of America.
Henry M. Jackson Foundation · USNaval Medical Research Command · USUnited States Agency for International Development · USLa Jolla Institute for Immunology · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A DNA prime/adenovirus boost malaria vaccine encoding Plasmodium falciparum strain 3D7 CSP and AMA1 elicited sterile clinical protection associated with CD8+ T cell interferon-gamma (IFN-γ) cells responses directed to HLA class 1-restricted AMA1 epitopes of the vaccine strain 3D7. Since a highly effective malaria vaccine must be broadly protective against multiple P. falciparum strains, we compared these AMA1 epitopes of two P. falciparum strains (7G8 and 3D7), which differ by single amino acid substitutions, in their ability to recall CD8+ T cell activities using ELISpot and flow cytometry/intracellular staining assays. The 7G8 variant peptides did not recall 3D7 vaccine-induced CD8+ T IFN-γ cell responses in these assays, suggesting that protection may be limited to the vaccine strain. The predicted MHC binding affinities of the 7G8 variant epitopes were similar to the 3D7 epitopes, suggesting that the amino acid substitutions of the 7G8 variants may have interfered with TCR recognition of the MHC:peptide complex or that the 7G8 variant may have acted as an altered peptide ligand. These results stress the importance of functional assays in defining protective epitopes. Clinical Trials Registrations: NCT00870987, NCT00392015.

Indexed as

Antigens, ProtozoanCD8-Positive T-LymphocytesEpitopesFlow CytometryHLA AntigensHLA-B AntigensHumansInterferon-gammaMalaria, FalciparumMalaria VaccinesMembrane ProteinsPlasmodium falciparumProtozoan ProteinsAntigens, Protozoanapical membrane antigen I, PlasmodiumEpitopesHLA AntigensHLA-B58HLA-B AntigensInterferon-gammaMalaria VaccinesMembrane ProteinsProtozoan Proteins

Identifiers

PMID27695088
PMCPMC5047630
OpenAlexW2528714541

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.